INCY vs TIGO Comparison

Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.

Millicom offers wireless and fixed-line telecom services primarily in smaller, less developed countries in Latin America. Countries served include Bolivia, Nicaragua, Panama, El Salvador, Guatemala, Paraguay, Colombia, Ecuador, Uruguay, and Honduras (67% but not controlled or consolidated in the firm's financial statements). The firm's wireless networks cover about 145 million people, serving nearly 60 million customers. Its fixed-line networks reach 22 million homes, serving about 5.6 million broadband customers. Increasingly, Millicom offers converged packages that include broadband with wireless services. The firm also formed a joint venture to acquire Telefónica's operations in Chile.